RxDoctor Payments Data

Jan Marie Kroh, MD

Dermatology · Olathe, KSNPI 1902836125

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 31 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by AbbVie at 45.3% of the total. Reporting peaked in 2024 at $273 and has fallen 78.1% since, to $60 in 2025. That places this record below the midpoint for dermatology clinicians in KS, where the typical reported total is $1,741.

$732in general payments, 2019–2025

Across 31 payments — averaging $23.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$332
  • Galderma Laboratories, L.p.$71
  • UCB, Inc.$53
  • Incyte Corporation$49
  • LEO Pharma Inc.$45
  • Lilly USA, LLC$39
  • plus $143 from 6 others

What the payments were for

  • Food & beverage$732100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$732 in reported general payments places this provider in the 30th percentile of 82 dermatology providers in Kansas.

See all dermatology providers in Kansas

Medicare billing

Part B allowed, 2024
$417,791
Medicare patients
1,142
Services billed
9,849

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira PenAdalimumab24$163,176
OtezlaApremilast21$104,314
Dupixent PenDupilumab13$48,646
Azelaic Acid60$7,159
Clobetasol Propionate107$5,742
Minoxidil476$5,093
Fluorouracil40$3,219
Betamethasone Dipropionate41$2,489
Fluticasone Propionate183$2,418
Minocycline Hcl126$2,369
Fluconazole150$1,587
Tretinoin30$1,530
Doxycycline Hyclate103$1,457
Triamcinolone Acetonide177$1,448
Ciclopirox40$1,362

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$24$104,31421 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 82 dermatology providers in Kansas.

Other dermatology in Olathe

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →